Gemtuzumab ozogamicin as maintenance therapy after autologous stem cell transplantation in elderly patients with acute myeloid leukaemia.

@article{Cascavilla2008GemtuzumabOA,
  title={Gemtuzumab ozogamicin as maintenance therapy after autologous stem cell transplantation in elderly patients with acute myeloid leukaemia.},
  author={Nicola Cascavilla and Giovanni D'Arena and Michele Mario Greco and Lorella Melillo and Emanuela Merla and Angelo Michele Carella},
  journal={British journal of haematology},
  year={2008},
  volume={142 5},
  pages={852-3}
}
Acute myeloid leukaemia (AML) has a dismal prognosis, particularly in older patients who make up a large proportion of the AML population. Induction therapy, typically consisting of cytarabine and anthracycline combination regimens, is the cornerstone of treatment and achieves a complete remission (CR) rate of 45–55% in older patients and a median survival of only 8–12 months (Roboz, 2007). Unfortunately, aggressive, postremission consolidation chemotherapy does not appear to improve survival… CONTINUE READING
3 Citations
9 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-9 of 9 references

The role of gemtuzumab ozogamicin in acute leukaemia therapy

  • Tsimberidous, A.-M, +4 authors H. Kantarjian
  • British Journal of haematology,
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…